Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
Successes and Challenges of NK Immunotherapy: Increasing Anti-tumor Efficacy describes the unique therapeutic applications of NK cells to fight cancers and eliminate the bulk and subset of cancer stem cells responsible for metastasis, relapse and recurrences. The book provides information on the development, engineering, mechanisms of action, response to various preclinical models, and applications in various clinical trials. Sections cover the development of highly engineered cytotoxic NK cells, their mechanisms of action, preclinical and clinical applications, the development and application of CAR-NK cells, and new NK-drug conjugates, also emphasizing that activated NK cells can target and kill highly resistant cancer stem cells.
Written by the leading experts on NK immunotherapy worldwide, this is a valuable resource for researchers, clinicians and members of the biomedical field who are interested in understanding novel and efficient therapies to fight cancers.
- Discusses the unique developmental applications of NK immunotherapy against cancers, which differs greatly from other types of immunotherapies
- Provides up-to-date and highly relevant information through chapters written by the leading researchers in the field
- Presents a significant number of schematic diagrams for easy understanding and reproducibility
Cancer researchers, medical scientists, clinicians, graduate students
General Introduction of Natural Killer cells
Section 1: Modulation of NK Antitumor Activities
1. Engineered Human Pluripotent Stem Cell-Derived NK Cells with Improved Anti-tumor Activity
2. The Cancer - NK cell Immunity Cycle
3. Immunometabolic reprogramming of NK cells for immunotherapy of solid tumors
4. Immunoregulation of NK cells: Similarities and Differences Compared to T cells
5. Tracking the decay of TGFb-resistant NK cells identifies an immune clock of innate cell aging
Section 2: Regulation of NK Antitumor Activities
6. Oncolytic virus therapy for cancer; role in activation of NK cells
7. Rendering NK cells resistant to immune suppression: genetic modification with a dominant negative receptor for TGF-Beta
8. Cystatin F, an inhibitor of cysteine cathepsins, regulates the cytotoxicity of NK cells
9. The NCR2-PCNA Immune Checkpoint and Natural Killer-based immunotherapy
10. Tumor derived soluble human NKG2D ligand mediated perturbations in NK cell metabolism and therapeutic implications
11. The expression of high affinity recombinant Fc receptors by engineered natural killer cells to enhance cancer cell killing by ADCC
Section 3: NK Antitumor Immunotherapy
12. The many key functions of Natural Killers cells in premalignant and malignant stages of tumorigenesis; when these gatekeepers are gone or defective anarchy ensues
13. Phenotypic plasticity: the emergence of cancer stem cells and collective cell migration
14. Stem cell-engineered invariant natural killer T cells for cancer immunotherapy
15. Natural killer cells in the glioblastoma stem cell niche microenvironment
16. CAR-redirected Cytokine-Induced Killer lymphocytes against sarcomas
17. The Effect of Natural Killer Cells on HIV-1 Rebound in Humanized Mice
Section 4: NK Antitumor Immunotherapy 2
18. NK cells are innate actors in the immunosurveillance of melanoma
19. Patients with prostate cancer associate with altered features of Natural Killer cells in terms of pro-angiogenic function and M2-like macrophage polarization capacity
20. New therapeutic approaches to target malignant gliomas
21. Mobilizing Human iNKT cells for Cancer Immunotherapies
22. Initial Innate Immune Responses to Tumor Metastasis
23. Regulating NK cell homeostasis and function by tumor associated NKG2D ligand MIC
24. Natural Killer Cells in Cancer Immunotherapy and Oncolytic Virotherapy
Section 5: General Concluding Remarks and Future Perspectives
- No. of pages:
- © Academic Press 2021
- 1st March 2021
- Academic Press
- Hardcover ISBN:
Benjamin Bonavida, PhD, has been involved in the field of immunology and cancer biology for several decades and has published extensively in the fields of cancer resistance, chemotherapy, immunotherapy, and various molecular approaches to circumvent the resistance of the cancer cells using sensitizing agents. Accordingly, he was the first to publish a book on tumor sensitization in 2008. More recently, Dr. Bonavida is the Series Editor of 3 series published by Elsevier/Academic Press (“Cancer Sensitizing Agents for Chemotherapy,” “Breaking Cancer Resistance to Therapeutic Antibodies,” and “Breaking Tolerance to Anti-Cancer Immunotherapy”) and several books have been published and many are in development. He has published extensively in the field of NK biology and cytotoxicity in the past, and many of these publications were in collaboration with the co-editor Dr. Anahid Jewett.
Professor, Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, USA
Dr. Anahid Jewett is well-known nationally and internationally for her contribution to the field of NK biology, tumor immunology and cancer immunotherapy. She serves on the editorial board of many prestigious journals and has been a reviewer on the board of National Institute of Health study sections. She holds several patents and has published more than 100 high impact journal articles, reviews, commentaries and book chapters in the field of cancer. Dr. Jewett’s major contributions to science and NK cell biology were the identification, characterization and the establishment of the concept of split anergy in NK cells, establishment of the role of NK cells in elimination, selection and differentiation of cancer stem cells as well as healthy stem cells, and methods to generate large numbers of super-charged NK cells which are in use currently in clinical trials of cancer patients.
National Institute of Health Study Sections, UCLA, USA
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.